Skip Nav Destination

Issue Archive

Select Year

Issue

Volume 8, Issue 8

April 23 2024

In this Issue

INSIDE BLOOD ADVANCES
CLINICAL TRIALS AND OBSERVATIONS
IMMUNOBIOLOGY AND IMMUNOTHERAPY
LYMPHOID NEOPLASIA
MYELOID NEOPLASIA
RED CELLS, IRON, AND ERYTHROPOIESIS
TRANSPLANTATION
RESEARCH LETTERS
ERRATA

INSIDE BLOOD ADVANCES

Survival for the fittest: guadecitabine in rel/ref AML
Clinical Trials & Observations

Joshua Sheehy,Steven W. Lane

View Articletitled, Survival for the fittest: guadecitabine in rel/ref AML

Better eat!

Nelson Chao

View Articletitled, Better eat!

Steroid tapering after GVHD Rx: not too fast, not too slow

Paul J. Martin

View Articletitled, Steroid tapering after GVHD Rx: not too fast, not too slow

CLINICAL TRIALS AND OBSERVATIONS

Thrombotic events associated with low baseline direct oral anticoagulant levels in atrial fibrillation: the MAS study
Clinical Trials & Observations

Sophie Testa,Gualtiero Palareti,Cristina Legnani,Claudia Dellanoce,Michela Cini,Oriana Paoletti,Antonio Ciampa,Emilia Antonucci,Daniela Poli,Rossella Morandini,Maurizio Tala,Paolo Chiarugi,Rita Carlotta Santoro,Angela Maria Iannone,Erica De Candia,Pasquale Pignatelli,Elena Maria Faioni,Antonio Chistolini,Maria del Pilar Esteban,Marco Marietta,Armando Tripodi,Alberto Tosetto,for the MAS study group

View Articletitled, Thrombotic events associated with low baseline direct oral anticoagulant levels in atrial fibrillation: the MAS study

Supplemental data

Six-year follow-up and subgroup analyses of a phase 2 trial of venetoclax for del(17p) chronic lymphocytic leukemia
Clinical Trials & Observations

Stephan Stilgenbauer,Eugen Tausch,Andrew W. Roberts,Matthew S. Davids,Barbara Eichhorst,Michael Hallek,Peter Hillmen,Christof Schneider,Johannes Schetelig,Sebastian Böttcher,Arnon P. Kater,Yanwen Jiang,Michelle Boyer,Relja Popovic,Majd T. Ghanim,Michael Moran,Wendy J. Sinai,Xifeng Wang,Nabanita Mukherjee,Brenda Chyla,William G. Wierda,John F. Seymour

View Articletitled, Six-year follow-up and subgroup analyses of a phase 2 trial of venetoclax for del(17p) chronic lymphocytic leukemia

Supplemental data

Guadecitabine vs TC in relapsed/refractory AML after intensive chemotherapy: a randomized phase 3 ASTRAL-2 trial
Clinical Trials & Observations

Gail J. Roboz,Guillermo Sanz,Elizabeth A. Griffiths,Karen Yee,Hagop Kantarjian,Christian Récher,Michael T. Byrne,Elżbieta Patkowska,Hee-Je Kim,Xavier Thomas,Ine Moors,Wendy Stock,Árpád Illés,Pierre Fenaux,Yasushi Miyazaki,Takahiro Yamauchi,Casey L. O'Connell,Yong Hao,Harold N. Keer,Mohammad Azab,Hartmut Döhner

View Articletitled, Guadecitabine vs TC in relapsed/refractory AML after intensive chemotherapy: a randomized phase 3 ASTRAL-2 trial

Supplemental data

IMMUNOBIOLOGY AND IMMUNOTHERAPY

Applying the EHA/EBMT grading for ICAHT after CAR-T: comparative incidence and association with infections and mortality

Kai Rejeski,Yucai Wang,Doris K. Hansen,Gloria Iacoboni,Emmanuel Bachy,Radhika Bansal,Olaf Penack,Fabian Müller,Wolfgang Bethge,Javier Munoz,Razan Mohty,Veit L. Bücklein,Pere Barba,Frederick L. Locke,Yi Lin,Michael D. Jain,Marion Subklewe

View Articletitled, Applying the EHA/EBMT grading for ICAHT after CAR-T: comparative incidence and association with infections and mortality

Supplemental data

Human Fc gamma receptor IIIA blockade inhibits platelet destruction in a humanized murine model of ITP

Lazaro Gil Gonzalez,Kevin D. Won,Zoya Tawhidi,Emma Cummins,Yoelys Cruz-Leal,Yaima Tundidor Cabado,Ulrich J. Sachs,Peter A. A. Norris,Yuexin Shan,Varsha Bhakta,Janessa Li,Ismael Samudio,Begonia Silva-Moreno,Liza Cerna-Portillo,Alequis Pavon Oro,Peter Bergqvist,Patrick Chan,Amy Moorehead,Michelle Sholzberg,William P. Sheffield,Alan H. Lazarus

View Articletitled, Human Fc gamma receptor IIIA blockade inhibits platelet destruction in a humanized murine model of ITP

Supplemental data

Comparison of antibody-based immunotherapeutics for malignant hematological disease in an experimental murine model

Karin Frebel,Jörn C. Albring,Anika Wohlgemuth,Christian Schwöppe,Stephan Hailfinger,Georg Lenz,Matthias Stelljes

View Articletitled, Comparison of antibody-based immunotherapeutics for malignant hematological disease in an experimental murine model

Supplemental data

In BTK, phosphorylated Y223 in the SH3 domain mirrors catalytic activity, but does not influence biological function

H. Yesid Estupiñán,Thibault Bouderlique,Chenfei He,Anna Berglöf,Andrea Cappelleri,Nicolai Frengen,Rula Zain,Mikael C. I. Karlsson,Robert Månsson,C. I. Edvard Smith

View Articletitled, In BTK, phosphorylated Y223 in the SH3 domain mirrors catalytic activity, but does not influence biological function

Supplemental data

Autophagy prevents graft failure during murine graft-versus-host disease

Katie E. Lineburg,Lucie Leveque-El Mouttie,Christopher R. Hunter,Laetitia Le Texier,Crystal McGirr,Bianca Teal,Bruce R. Blazar,Steven W. Lane,Geoffrey R. Hill,Jean-Pierre Lévesque,Kelli P. A. MacDonald

View Articletitled, Autophagy prevents graft failure during murine graft-versus-host disease

Supplemental data

LYMPHOID NEOPLASIA

Tyrosine kinase inhibitor resistance in de novo BCR::ABL1–positive BCP-ALL beyond kinase domain mutations
Clinical Trials & Observations

Inge van Outersterp,Judith M. Boer,Cesca van de Ven,Caitlin E. J. Reichert,Aurelie Boeree,Brian Kruisinga,Hester A. de Groot-Kruseman,Gabriele Escherich,Aniko Sijs-Szabo,Anita W. Rijneveld,Monique L. den Boer

View Articletitled, Tyrosine kinase inhibitor resistance in de novo BCR::ABL1–positive BCP-ALL beyond kinase domain mutations

Supplemental data

A molecular circuit linking the BCR to the NAD biosynthetic enzyme NAMPT is an actionable target in Richter syndrome

Vincenzo G. Messana,Amelia Fascì,Nicoletta Vitale,Matilde Micillo,Matteo Rovere,Noemi A. Pesce,Claudio Martines,Dimitar G. Efremov,Tiziana Vaisitti,Silvia Deaglio

View Articletitled, A molecular circuit linking the BCR to the NAD biosynthetic enzyme NAMPT is an actionable target in Richter syndrome

Supplemental data

Sinonasal DLBCL: molecular profiling identifies subtypes with distinctive prognosis and targetable genetic features

Patrick R. G. Eriksen,Fleur de Groot,Erik Clasen-Linde,Peter de Nully Brown,Ruben de Groen,Linea C. Melchior,Andrea D. Maier,Marthe Minderman,Joost S. P. Vermaat,Christian von Buchwald,Steven T. Pals,Steffen Heegaard

View Articletitled, Sinonasal DLBCL: molecular profiling identifies subtypes with distinctive prognosis and targetable genetic features

Supplemental data

Monocytes in leukapheresis products affect the outcome of CD19–targeted CAR T-cell therapy in patients with lymphoma

Cristiana Carniti,Nicole M. Caldarelli,Luca Agnelli,Tommaso Torelli,Silva Ljevar,Sadhana Jonnalagadda,Giada Zanirato,Eugenio Fardella,Federico Stella,Daniele Lorenzini,Silvia Brich,Flavio Arienti,Anna Dodero,Annalisa Chiappella,Martina Magni,Paolo Corradini

View Articletitled, Monocytes in leukapheresis products affect the outcome of CD19–targeted CAR T-cell therapy in patients with lymphoma

Supplemental data

MYELOID NEOPLASIA

Structural variants involving MLLT10 fusion are associated with adverse outcomes in pediatric acute myeloid leukemia

Oussama Abla,Rhonda E. Ries,Tim Triche, Jr,Robert B. Gerbing,Betsy Hirsch,Susana Raimondi,Todd Cooper,Jason E. Farrar,Nathaniel Buteyn,Lauren M. Harmon,Hong Wen,Aniruddha J. Deshpande,E. Anders Kolb,Alan S. Gamis,Richard Aplenc,Todd Alonzo,Soheil Meshinchi

View Articletitled, Structural variants involving MLLT10 fusion are associated with adverse outcomes in pediatric acute myeloid leukemia

Supplemental data

RED CELLS, IRON, AND ERYTHROPOIESIS

A human anti-matriptase-2 antibody limits iron overload, α-globin aggregates, and splenomegaly in β-thalassemic mice

Matthew Wake,Anaïs Palin,Audrey Belot,Mathieu Berger,Megane Lorgouilloux,Margot Bichon,Jonathan Papworth,Luke Bayliss,Benjamin Grimshaw,Natalie Rynkiewicz,Jemima Paterson,Alicia Poindron,Erin Spearing,Emily Carter,Robyne Hudson,Millie Campbell,Verena Petzer,Céline Besson-Fournier,Chloé Latour,Amélie Largounez,Ophélie Gourbeyre,Alexis Fay,Hélène Coppin,Marie-Paule Roth,Igor Theurl,Volker Germaschewski,Delphine Meynard

View Articletitled, A human anti-matriptase-2 antibody limits iron overload, α-globin aggregates, and splenomegaly in β-thalassemic mice

Supplemental data

TRANSPLANTATION

Immunophenotypic predictors of influenza vaccine immunogenicity in pediatric hematopoietic cell transplant recipients

Justin Z. Amarin,Daniel E. Dulek,Joshua Simmons,Haya Hayek,James D. Chappell,Cindy Hager Nochowicz,Carrie L. Kitko,Jennifer E. Schuster,Flor M. Muñoz,Claire E. Bocchini,Elizabeth A. Moulton,Susan E. Coffin,Jason L. Freedman,Monica I. Ardura,Rachel L. Wattier,Gabriela Maron,Michael Grimley,Grant Paulsen,Lara Danziger-Isakov,Paul A. Carpenter,Janet A. Englund,Natasha B. Halasa,Andrew J. Spieker,Spyros A. Kalams,for the Pediatric HCT Flu Study Group

View Articletitled, Immunophenotypic predictors of influenza vaccine immunogenicity in pediatric hematopoietic cell transplant recipients

Supplemental data

Incidence and risk factors of pain crisis after hematopoietic cell transplantation for sickle cell disease

Lakshmanan Krishnamurti,Jingchen Liang,Zili He,Yanhong Deng,Vineetha R. Nallagatla,Rohaum Hamidi,Aron Flagg,Niketa Shah

View Articletitled, Incidence and risk factors of pain crisis after hematopoietic cell transplantation for sickle cell disease

Supplemental data

Flares of acute graft-versus-host disease: a Mount Sinai Acute GVHD International Consortium analysis

Yu Akahoshi,Nikolaos Spyrou,Matthias Hoepting,Paibel Aguayo-Hiraldo,Francis Ayuk,Chantiya Chanswangphuwana,Hannah K. Choe,Matthias Eder,Aaron M. Etra,Stephan A. Grupp,Elizabeth O. Hexner,William J. Hogan,Carrie L. Kitko,Sabrina Kraus,Monzr M. Al Malki,Pietro Merli,Muna Qayed,Ran Reshef,Tal Schechter,Evelyn Ullrich,Ingrid Vasova,Matthias Wölfl,Robert Zeiser,Janna Baez,Rahnuma Beheshti,Gilbert Eng,Sigrun Gleich,Stelios Kasikis,Nikolaos Katsivelos,Steven Kowalyk,George Morales,Rachel Young,Zachariah DeFilipp,James L. M. Ferrara,John E. Levine,Ryotaro Nakamura

View Articletitled, Flares of acute graft-versus-host disease: a Mount Sinai Acute GVHD International Consortium analysis

Supplemental data

RESEARCH LETTERS

Real-world applicability of the International Metabolic Prognostic Index in DLBCL: a validation cohort study

Daisuke Ikeda,Mitsuaki Oura,Atsushi Uehara,Rikako Tabata,Kentaro Narita,Masami Takeuchi,Youichi Machida,Kosei Matsue

View Articletitled, Real-world applicability of the International Metabolic Prognostic Index in DLBCL: a validation cohort study

Supplemental data

Maintenance therapy for early loss of B-cell aplasia after anti-CD19 CAR T-cell therapy

Maria Gabelli,Macarena Oporto-Espuelas,Saskia Burridge,Jan Chu,Susan Farish,Emma Hedges,Kirsty Ware,Lindsey Williams,Lindsey Young,Rajesh Alajangi,Philip Ancliff,Jack Bartram,Denise Bonney,Lenka Chenchara,Robert Chiesa,Chiara Cugno,Katharine Hodby,Katarzyna A. Jalowiec,Arina Lazareva,Giovanna Lucchini,Oana C. Mirci-Danicar,Khushnuma Mullanfiroze,Vesna Pavasovic,Anupama Rao,Kanchan Rao,Lynne Riley,Sujith Samarasinghe,Geoff Shenton,Juliana Silva,Ajay Vora,Rachael Hough,Persis J. Amrolia,Sara Ghorashian

View Articletitled, Maintenance therapy for early loss of B-cell aplasia after anti-CD19 CAR T-cell therapy

Supplemental data

Haploidentical bone marrow transplantation for AML in remission after TBF conditioning: a long-term follow-up
Clinical Trials & Observations

Anna M. Raiola,Carmen Di Grazia,Alida Dominietto,Stefania Bregante,Sabrina Giammarco,Riccardo Varaldo,Federica Sorà,Elisabetta Metafuni,Maria A. Limongiello,Antonella Laudisi,Monica Passannante,Eugenio Galli,Massimiliano Gambella,Simona Sica,Andrea Bacigalupo,Emanuele Angelucci,Patrizia Chiusolo

View Articletitled, Haploidentical bone marrow transplantation for AML in remission after TBF conditioning: a long-term follow-up

ERRATA

Sahin I, Kawano Y, Sklavenitis-Pistofidis R, et al. Citron Rho-interacting kinase silencing causes cytokinesis failure and reduces tumor growth in multiple myeloma. Blood Adv. 2019;3(7):995-1002.

View Articletitled, Sahin I, Kawano Y, Sklavenitis-Pistofidis R, et al. Citron Rho-interacting kinase silencing causes cytokinesis failure and reduces tumor growth in multiple myeloma. Blood Adv. 2019;3(7):995-1002.

Jian Y, Chang L, Shi M-X, et al. Pomalidomide, bortezomib, and dexamethasone for newly diagnosed multiple myeloma patients with renal impairment. Blood Adv. 2023;7(24):7581-7584.

View Articletitled, Jian Y, Chang L, Shi M-X, et al. Pomalidomide, bortezomib, and dexamethasone for newly diagnosed multiple myeloma patients with renal impairment. Blood Adv. 2023;7(24):7581-7584.

Cover Image

Cover Image

Immunofluorescence staining of a lymph node section from a wild-type mouse displaying TCRβ (green) and B220 (red) markers, in comparative studies of the B- and T-cell spatial distribution in the CRISPR-Cas9–mediated, knockin Y223F-Bruton’s tyrosine kinase mouse model. See the article by Estupiñán et al.

All Issues

Email alerts

Continuous Publishing Alert

New Journal Content Alert

Latest
Most Read
Most Cited

Modified Delphi Panel Consensus Recommendations for Management of Severe Aplastic Anemia

Myosin-1C augments secretion of von Willebrand factor by linking contractile actomyosin machinery to the plasma membrane

Venous Thromboembolism Characteristics and Outcomes Among RIETE Patients Tested & Untested for Inherited Thrombophilia

DISPLACE Study Shows Poor Quality of Transcranial Doppler Ultrasound for Stroke Risk Screening in Sickle Cell Anemia

Defining Primary Refractory Large B-cell Lymphoma

Table of Contents

INSIDE BLOOD ADVANCES

Survival for the fittest: guadecitabine in rel/ref AML
Clinical Trials & Observations

Better eat!

Steroid tapering after GVHD Rx: not too fast, not too slow

CLINICAL TRIALS AND OBSERVATIONS

Thrombotic events associated with low baseline direct oral anticoagulant levels in atrial fibrillation: the MAS study
Clinical Trials & Observations

Six-year follow-up and subgroup analyses of a phase 2 trial of venetoclax for del(17p) chronic lymphocytic leukemia
Clinical Trials & Observations

Guadecitabine vs TC in relapsed/refractory AML after intensive chemotherapy: a randomized phase 3 ASTRAL-2 trial
Clinical Trials & Observations

IMMUNOBIOLOGY AND IMMUNOTHERAPY

Applying the EHA/EBMT grading for ICAHT after CAR-T: comparative incidence and association with infections and mortality

Human Fc gamma receptor IIIA blockade inhibits platelet destruction in a humanized murine model of ITP

Comparison of antibody-based immunotherapeutics for malignant hematological disease in an experimental murine model

In BTK, phosphorylated Y223 in the SH3 domain mirrors catalytic activity, but does not influence biological function

Autophagy prevents graft failure during murine graft-versus-host disease

LYMPHOID NEOPLASIA

Tyrosine kinase inhibitor resistance in de novo BCR::ABL1–positive BCP-ALL beyond kinase domain mutations
Clinical Trials & Observations

A molecular circuit linking the BCR to the NAD biosynthetic enzyme NAMPT is an actionable target in Richter syndrome

Sinonasal DLBCL: molecular profiling identifies subtypes with distinctive prognosis and targetable genetic features

Monocytes in leukapheresis products affect the outcome of CD19–targeted CAR T-cell therapy in patients with lymphoma

MYELOID NEOPLASIA

Structural variants involving MLLT10 fusion are associated with adverse outcomes in pediatric acute myeloid leukemia

RED CELLS, IRON, AND ERYTHROPOIESIS

A human anti-matriptase-2 antibody limits iron overload, α-globin aggregates, and splenomegaly in β-thalassemic mice

TRANSPLANTATION

Immunophenotypic predictors of influenza vaccine immunogenicity in pediatric hematopoietic cell transplant recipients

Incidence and risk factors of pain crisis after hematopoietic cell transplantation for sickle cell disease

Flares of acute graft-versus-host disease: a Mount Sinai Acute GVHD International Consortium analysis

RESEARCH LETTERS

Real-world applicability of the International Metabolic Prognostic Index in DLBCL: a validation cohort study

Maintenance therapy for early loss of B-cell aplasia after anti-CD19 CAR T-cell therapy

Haploidentical bone marrow transplantation for AML in remission after TBF conditioning: a long-term follow-up
Clinical Trials & Observations

ERRATA

Sahin I, Kawano Y, Sklavenitis-Pistofidis R, et al. Citron Rho-interacting kinase silencing causes cytokinesis failure and reduces tumor growth in multiple myeloma. Blood Adv. 2019;3(7):995-1002.

Jian Y, Chang L, Shi M-X, et al. Pomalidomide, bortezomib, and dexamethasone for newly diagnosed multiple myeloma patients with renal impairment. Blood Adv. 2023;7(24):7581-7584.

Email alerts

ASH Publications

American Society of Hematology

Issue Archive

Table of Contents

INSIDE BLOOD ADVANCES

Survival for the fittest: guadecitabine in rel/ref AML Clinical Trials & Observations

CLINICAL TRIALS AND OBSERVATIONS

Thrombotic events associated with low baseline direct oral anticoagulant levels in atrial fibrillation: the MAS study Clinical Trials & Observations

Six-year follow-up and subgroup analyses of a phase 2 trial of venetoclax for del(17p) chronic lymphocytic leukemia Clinical Trials & Observations

Guadecitabine vs TC in relapsed/refractory AML after intensive chemotherapy: a randomized phase 3 ASTRAL-2 trial Clinical Trials & Observations

IMMUNOBIOLOGY AND IMMUNOTHERAPY

LYMPHOID NEOPLASIA

Tyrosine kinase inhibitor resistance in de novo BCR::ABL1–positive BCP-ALL beyond kinase domain mutations Clinical Trials & Observations

MYELOID NEOPLASIA

RED CELLS, IRON, AND ERYTHROPOIESIS

TRANSPLANTATION

RESEARCH LETTERS

Haploidentical bone marrow transplantation for AML in remission after TBF conditioning: a long-term follow-up Clinical Trials & Observations

ERRATA

Cover Image

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only

Survival for the fittest: guadecitabine in rel/ref AML
Clinical Trials & Observations

Thrombotic events associated with low baseline direct oral anticoagulant levels in atrial fibrillation: the MAS study
Clinical Trials & Observations

Six-year follow-up and subgroup analyses of a phase 2 trial of venetoclax for del(17p) chronic lymphocytic leukemia
Clinical Trials & Observations

Guadecitabine vs TC in relapsed/refractory AML after intensive chemotherapy: a randomized phase 3 ASTRAL-2 trial
Clinical Trials & Observations

Tyrosine kinase inhibitor resistance in de novo BCR::ABL1–positive BCP-ALL beyond kinase domain mutations
Clinical Trials & Observations

Haploidentical bone marrow transplantation for AML in remission after TBF conditioning: a long-term follow-up
Clinical Trials & Observations